Celyad Ocology has voluntarily paused a clinical study evaluating its off-the-shelf CAR T-cell therapy in colorectal cancer following the report of two patient deaths. The investigation is ongoing, but the company said that both patients exhibited “similar pulmonary findings.”
In a recent interview, executives from two early-stage biopharma companies said that off-the-shelf approach is the only way to drive down the cost of novel cell and gene therapies like CAR-T.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Allogeneic CAR-Ts could serve an important niche - particularly for patients who can't receive autologous CAR-Ts - but the earliness of the data makes conclusions tough to draw.